HOME >> BIOLOGY >> NEWS
Scientists making advances in cancer to receive international awards

as related to drug discovery that has implications for the improved care of cancer patients. The prize was established to honor Dr. Bruce F. Cain, whose scientific interests involved the design, synthesis, and biological evaluation of potential anti-tumor drugs. Adams will present his lecture, "The Proteasome and Cancer: The Discovery and Development of VELCADE," at 9:00 a.m., April 5, in Ballroom A-B of the Washington Convention Center.

Nicholas Edward Day, Ph.D., Professor of Epidemiology, University of Cambridge, UK, will be honored with the 15th AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention. With this award, Day will be recognized for developing and widely applying many of the statistical methods that support modern cancer epidemiology. The award is intended to distinguish outstanding achievements in the fields of epidemiology, biomarkers, and prevention. Day will present his lecture on "Cancer Prevention: Past Perspectives and Future Directions," at 5:30 p.m. on Tuesday, April 4, in Hall D of the Washington Convention Center.

Merrill J. Egorin., M.D., Professor of Medicine and Pharmacology, University of Pittsburgh Cancer Institute, Pittsburgh, Pa., will be honored in recognition of his outstanding achievements in clinical and preclinical cancer pharmacology. Dr. Egorin will be the recipient of the 11th AACR-Joseph H. Burchenal Clinical Research Award, which recognizes outstanding achievements in clinical cancer research. The award's namesake was an honorary member and past president of AACR, as well as a major figure in clinical cancer research. Dr. Egorin's lecture, "Keep on Trucking: Antineoplastic Clinical Pharmacology--Where We Have Been, and Where We Need to Go," is to be presented at 8:00 a.m., Wednesday, April 5, in Ballroom A-B of the Washington Convention Center.

Ivan Dikic, M.D., Ph.D., a professor in the Institute for Biochemist
'"/>

Contact: Yarissa Ortiz
ortiz@aacr.org
215-440-9300
American Association for Cancer Research
24-Mar-2006


Page: 1 2 3 4

Related biology news :

1. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
2. Scientists prove that disputed Korean stem cell line comes from an unfertilized egg and not cloning
3. Scientists move closer to bio-engineered bladders
4. Scientists find stem cell switch
5. Scientists discover new way to study nanostructures
6. Scientists a step closer to understanding how anaesthetics work in the brain
7. Scientists to make news at Computational Biology Conference
8. Accident-prone? Scientists link brain function to knee injuries
9. Scientists take next step in understanding potential target for ovarian cancer treatment
10. Scientists find brown fat master switch
11. Scientists identify 2 distinct Parkinsons networks

Post Your Comments:
(Date:7/23/2015)... BEDFORD, Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... services, today reported financial results for its second quarter ended ... quarter of 2015 was $4.5 million, a decrease of 33% ...  Net income in the second quarter of 2015 was $0.3 ... million, or $0.04 per diluted share, in the same period ...
(Date:7/21/2015)... , July 21, 2015 Passwords ... as seen in the recent U.S. Office of ... solution to the infosec conundrum, but developers and ... stored. To address this dilemma, Biometrics-as-a-Service provider HYPR ... Biometric Tokenization SDK for third party integration. ...
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
(Date:7/30/2015)... Senomyx , Inc. (NASDAQ: SNMX ), a leading ... and commercialize novel flavor ingredients for the food, beverage, ... the second quarter 2015. "Moving into ... to achieve our commercial and financial goals," stated John ... "Since our last quarterly earnings report, our two partners ...
(Date:7/30/2015)... -- HIGHLIGHTS:Q2 2015 Results (all changes are ... sales were $697 million compared to $701 million in ... 8%, and changes in foreign currency exchange rates decreased ... , By business unit, organic sales growth was ... SAFC Commercial. , Reported diluted EPS was $0.98 ...
(Date:7/30/2015)... NH (PRWEB) , ... July 30, 2015 , ... ... homogenizer for advanced fluid applications and designed for continuous operation up to 1500 ... and sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L ...
(Date:7/29/2015)... -- According to a new market research report, ... (2015-2020), , published by Mordor Intelligence, the Global market is ... of 2020, with North America being ... the global market size. The Global market for Stem Cells ... the period of (2015-2020).      (Logo: http://photos.prnewswire.com/prnh/20150428/740799) , ...
Breaking Biology Technology:SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3
Cached News: